Updated time: 2024-12-13 14:41:30
14A-1090511
2020-08-13
TW I861557、US Provisional
To control the outbreaks of emerging infectious diseases such as COVID-19 and previously pandemic H1N1 2009, etc., new vaccine technologies able to rapidly create an effective vaccine and move into large-scale manufacture is vital to the public health, economics, and national security. Virus-like particles (VLPs) aminate the structure of authentic viruses yet devoid of the viral genome and viral hazard during manufacture, regarded as a superb subunit vaccine. Assembly of enveloped VLPs is technically more complex than those without lipid envelops and requires concurrent over-expression of multiple viral proteins in the same cell. This technology enables one-step recombination of multiple genes into a premade cell line for large-scale production of VLPs from mammalian and insect cells.
- Non-viral mediated gene transduction.
- Faster recombination of multiple genes in one-step.
- Mammalian posttranslational modifications, correct folding, and assembly, all-in-one.
- Viral vaccine or diagnostic antigens.
- Antibody.
- Recombinant protein drugs.
Pei-Wen Hsiao, Yu-Chih Yang, Yi-Chun Yeh
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Virus-like particle stably expressed by animal cells as vaccine antigen against COVID-19 and influenza virus